Will Radius VSM Recalls and FDA Scrutiny Change Masimo's (MASI) Innovation-Led Stability Narrative?

• In February 2026, Masimo Corporation voluntarily initiated Class II recalls of several Radius VSM ECG and disposable blood pressure cuff products worldwide after identifying issues with ECG alarm accuracy and rough cuff edges that could cause skin irritation, with the US FDA classifying the action in July and the process still ongoing.
• The recalls highlight operational and quality-control challenges that could affect clinician confidence in Masimo’s monitoring platforms, especially as the company seeks broader adoption in hospitals and remote-care settings.
• We’ll now examine how these Radius VSM quality issues intersect with Masimo’s innovation-led investment narrative and expectations for more stable earnings.

Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Masimo Investment Narrative Recap

To own Masimo, you have to believe its patient monitoring ecosystem can sustain premium pricing and adoption despite uneven earnings and governance changes. The Radius VSM Class II recalls add another operational wrinkle but, given their limited scale and voluntary nature, they do not appear to alter the near term catalyst around Masimo’s integration as a standalone unit inside Danaher or the broader risk that hospital contract timing and competition keep revenue growth relatively lumpy.

The news also sits alongside Masimo’s pending US$33.75 million settlement in the Vazquez v. Masimo class action, which remains subject to court approval. Together, these developments keep regulatory and legal scrutiny front of mind for a business that is trying to convert its innovation pipeline and clinical data, such as the NeoPODS NICU study, into steadier earnings and improved confidence in its long term monitoring platforms.

But investors should be aware that hospital contract cycles and competitive bids can still...

Read the full narrative on Masimo (it's free!)

Masimo's narrative projects $1.9 billion revenue and $311.9 million earnings by 2029. This requires 6.5% yearly revenue growth and about a $95 million earnings increase from $216.8 million today.

Uncover how Masimo's forecasts yield a $180.00 fair value, in line with its current price.

Exploring Other Perspectives

Simply Wall St Community members currently see Masimo’s fair value between US$146.98 and US$180 across 2 independent views, showing how far opinions can stretch. Set this against Masimo’s dependence on slow moving hospital contract cycles, and you can see why it pays to weigh several different expectations about how consistently the company can grow.

Explore 2 other fair value estimates on Masimo - why the stock might be worth as much as $180.00!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Masimo research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Masimo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Masimo's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com